WallStSmart

ADC Therapeutics SA (ADCT)vsTakeda Pharmaceutical Co Ltd ADR (TAK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Takeda Pharmaceutical Co Ltd ADR generates 5690737% more annual revenue ($4.51T vs $79.17M). TAK leads profitability with a -3.4% profit margin vs -173.0%. TAK earns a higher WallStSmart Score of 57/100 (C).

ADCT

Avoid

23

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -6.89

TAK

Buy

57

out of 100

Grade: C

Growth: 6.7Profit: 4.0Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: 1.20

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ADCT1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.5410/10

Conservative balance sheet, low leverage

TAK4 strengths · Avg: 9.8/10
PEG RatioValuation
0.4510/10

Growing faster than its price suggests

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

EPS GrowthGrowth
330.2%10/10

Earnings expanding 330.2% YoY

Market CapQuality
$55.95B9/10

Large-cap with strong market position

Areas to Watch

ADCT4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$161.53M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-706.0%2/10

ROE of -706.0% — below average capital efficiency

Revenue GrowthGrowth
-9.5%2/10

Revenue declined 9.5%

TAK4 concerns · Avg: 2.8/10
Revenue GrowthGrowth
3.9%4/10

3.9% revenue growth

Return on EquityProfitability
2.5%3/10

ROE of 2.5% — below average capital efficiency

Free Cash FlowQuality
$-26.01B2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
1.202/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ADCT

The strongest argument for ADCT centers on Debt/Equity.

Bull Case : TAK

The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.

Bear Case : ADCT

The primary concerns for ADCT are EPS Growth, Market Cap, Return on Equity.

Bear Case : TAK

The primary concerns for TAK are Revenue Growth, Return on Equity, Free Cash Flow.

Key Dynamics to Monitor

ADCT carries more volatility with a beta of 1.88 — expect wider price swings.

TAK is growing revenue faster at 3.9% — sustainability is the question.

ADCT generates stronger free cash flow (-30M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TAK scores higher overall (57/100 vs 23/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ADC Therapeutics SA

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.

Visit Website →

Takeda Pharmaceutical Co Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?